Clinical Guides
Vulvovaginal Candidiasis
An India-focused, source-grounded guide to confirming vulvovaginal candidiasis, separating uncomplicated from complicated disease and prescribing safely in pregnancy, recurrence and non-albicans infection.
MedNext Academy | 15 min read
Vulvovaginal Candidiasis
An India-focused, source-grounded guide to confirming vulvovaginal candidiasis, separating uncomplicated from complicated disease and prescribing safely in pregnancy, recurrence and non-albicans infection.
Summary
Vulvovaginal candidiasis (VVC) is symptomatic inflammation of the vulva and vagina caused by overgrowth of Candida, most often Candida albicans. Candida may normally colonise the vagina, so detecting yeast without compatible symptoms and signs does not establish disease or require treatment. Typical VVC causes intense vulval itch, soreness, erythema, oedema, fissures, external dysuria and dyspareunia; discharge may be thick and white, but none of these features is specific. Vaginal pH is usually below 4.5. Confirm with budding yeast, hyphae or pseudohyphae on saline or potassium-hydroxide microscopy, or culture or a validated molecular test when microscopy is negative or disease is complicated.
Classify before treating. Uncomplicated VVC is sporadic or infrequent, mild to moderate, likely C. albicans and occurs in a non-immunocompromised patient. Complicated VVC includes recurrent disease, severe inflammation, non-albicans species or important host factors such as poorly controlled diabetes or immunosuppression. The category changes diagnostic effort, treatment duration and follow-up. Pregnancy also changes prescribing: WHO 2024 recommends topical clotrimazole or nystatin options and oral fluconazole should not be used for routine VVC in pregnancy.
VVC is not usually acquired through sexual intercourse, and routine treatment of an asymptomatic partner is not recommended. Repeated self-diagnosis is unreliable: BV, trichomoniasis, cervicitis, contact dermatitis, lichen sclerosus, genitourinary syndrome of menopause and other inflammatory vaginitis can mimic thrush. Recurrence shortly after over-the-counter treatment needs examination and testing rather than a stronger empirical combination. Treatment uses an effective topical azole or, in suitable nonpregnant patients, an oral azole; complicated disease may need longer induction, maintenance or species-directed care. This guide is educational. A registered clinician must verify pregnancy, liver disease, interactions, species, resistance, current Indian licensing and the NACO pathway before prescribing.
How Common Is It?
VVC is common worldwide and affects millions of people, but precise estimates vary with definition. Symptom surveys overcount because itch and white discharge have many causes; cultures overcount because Candida colonisation can be asymptomatic. CDC guidance estimates that most women experience at least one episode and a substantial minority experience more than one, but those figures come from heterogeneous populations and should not be presented as a verified contemporary India-specific prevalence. NACO's 2024 national STI/RTI guideline identifies Candida among the common causes of vaginal discharge syndrome, confirming its service importance in India without implying every discharge is candidiasis.
Most episodes are uncomplicated C. albicans disease. CDC estimates complicated VVC at roughly 10% to 20% of cases and recurrent VVC, defined there as three or more symptomatic episodes in under one year, at under 5%. Non-albicans Candida accounts for a larger share of recurrent disease than sporadic disease and can be harder to recognise on microscopy and less responsive to conventional azoles. These are population estimates, not a substitute for species identification in treatment failure.
Pregnancy, recent antibiotics and diabetes change attendance patterns, while ready access to over-the-counter antifungals creates a hidden burden of self-treated symptoms. Some apparent recurrences are repeated irritant dermatitis from topical products or a persistent non-Candida diagnosis. Conversely, lack of microscopy or culture can lead to broad syndromic treatment that includes an antifungal without proving yeast.
Clinical burden includes sleep loss, sexual pain, dysuria, distress and repeated cost. Recurrent disease can have a major quality-of-life effect despite not being invasive candidiasis. Vulvovaginal disease in an otherwise stable patient is distinct from Candida bloodstream or organ infection; one does not ordinarily progress into the other. The useful epidemiological message is that VVC is common enough to recognise but nonspecific enough that persistent or recurrent symptoms deserve confirmation.
Risk Factors
Candida disease occurs when colonising yeast overgrows or host-vaginal conditions permit inflammation. Antibiotics can disrupt bacterial flora that normally constrain yeast. Pregnancy and other hormonal changes influence the vaginal environment. Poorly controlled diabetes, immunodeficiency, HIV-related immune compromise, corticosteroids and other immunosuppressive therapy increase the likelihood of complicated, persistent or recurrent disease. Yet most otherwise healthy patients with uncomplicated VVC have no clear precipitant, and absence of a risk factor does not exclude it.
Recurrent VVC may be idiopathic or associated with frequent antibiotic exposure, diabetes or host factors. Non-albicans species are more common in recurrent disease. Inadequate treatment, poor adherence, an incorrect diagnosis and repeated exposure to irritant creams can appear as resistance. Azole resistance in C. albicans is increasingly recognised, so continued symptoms with positive culture after maintenance therapy should prompt susceptibility testing where available and specialist care.
VVC is not normally considered an STI. Sexual activity can trigger symptoms through friction or local ecological change, and a symptomatic partner can have balanitis, but an asymptomatic partner is not a routine reservoir requiring treatment. Tight or occlusive clothing, prolonged damp clothing and harsh scented products may worsen moisture or irritation; advice can improve comfort, but evidence does not support blaming underwear or personal hygiene as the cause of every episode. Douching is unnecessary and may disturb vaginal ecology.
Pregnancy is both a risk context and a prescribing constraint. Oral fluconazole is avoided for routine VVC during pregnancy; use recommended topical therapy. Consider pregnancy before any oral azole. Liver disease, QT-risk medicines and drugs metabolised through relevant cytochrome pathways affect oral-azole safety. Recurrence should trigger a diabetes review when clinically indicated, but universal extensive immune testing is not required for one typical episode. Risk assessment must remain proportionate and non-stigmatising.
Diagnosis
Symptoms alone are not specific enough to diagnose VVC reliably. Confirm the inflammatory syndrome and demonstrate yeast where feasible, especially in recurrent, severe, pregnancy-associated, non-responsive or immunocompromised cases. Obtain specimens before antifungal treatment when possible because self-treatment can reduce yield.
History
Ask about predominant itch, soreness, external burning with urine, superficial dyspareunia, discharge and sleep or functional impact. Record onset, prior confirmed episodes, treatments and response. A recurrence within two months of over-the-counter therapy warrants clinical review. Ask about odour, lower abdominal pain, fever, postcoital or intermenstrual bleeding, ulcers and urinary frequency because these suggest alternatives. Document last menstrual period, pregnancy possibility, contraception, recent antibiotics, diabetes control, HIV or immunosuppression, corticosteroids, liver disease, allergies and interacting medicines. Ask about douching, soaps, pads and multiple topical products. Take a confidential sexual and STI history without implying VVC is sexually transmitted.
Examination
With consent and a chaperone, inspect for vulval erythema, oedema, fissures, excoriations, adherent discharge, dermatosis, ulcers or contact reaction. Severe VVC has extensive erythema, oedema, excoriation or fissure formation. Speculum examination can show thick curdy discharge and vaginal inflammation and helps identify BV-like discharge, trichomoniasis, cervicitis, bleeding or foreign body. Pelvic pain or fever requires bimanual assessment for PID; these are not typical uncomplicated VVC features.
Investigations
Measure vaginal pH from the lateral wall; VVC usually has pH below 4.5, while BV and trichomoniasis commonly raise it. Examine saline and 10% potassium-hydroxide preparations for budding yeast, hyphae or pseudohyphae; KOH clears cellular material. A negative wet mount does not exclude disease. If symptoms and signs persist, obtain yeast culture, the reference standard, or a validated molecular assay. In complicated VVC, culture or PCR should identify species; Candida glabrata does not form typical hyphae and may be missed. Consider susceptibility testing for persistent culture-positive symptoms despite maintenance. Do not treat a positive culture without compatible disease. Test for BV, trichomoniasis, cervicitis, glucose abnormality, HIV or other conditions according to findings and risk.
Differential Diagnosis
Bacterial vaginosis usually causes thin homogeneous malodorous discharge with pH above 4.5 and clue cells, with less intense vulval inflammation. Trichomoniasis can cause malodorous yellow-green discharge, irritation, dysuria and cervical punctate erythema and is better detected by NAAT than wet mount. Mixed infection can occur. Physiological discharge is clear or white without itch, soreness, odour or bleeding. A thick white appearance alone does not distinguish colonisation, VVC and normal secretion.
Cervicitis causes mucopurulent endocervical discharge, friability or postcoital bleeding and may be asymptomatic. Lower abdominal pain, fever, deep dyspareunia or cervical-motion, uterine or adnexal tenderness suggests PID. Genital herpes can cause burning, dysuria and fissure-like lesions before vesicles are obvious. Urinary tract infection causes internal dysuria, frequency and urgency, whereas VVC more often burns externally as urine contacts inflamed skin.
Contact dermatitis from soaps, pads, detergents, lubricants, topical anaesthetics or repeated azole products can closely mimic candidiasis. Lichen sclerosus, lichen planus, eczema, psoriasis and vulvodynia cause persistent vulval symptoms and need careful visual examination, sometimes biopsy. Genitourinary syndrome of menopause causes dryness, burning, dyspareunia and elevated pH. Desquamative inflammatory or aerobic vaginitis causes inflammation and abnormal discharge with different microscopy. A retained foreign body produces offensive discharge.
Non-albicans Candida on culture may represent colonisation, especially when symptoms are minimal. Exclude other causes before attributing persistent symptoms to it. Recurrent symptoms can reflect inadequate species diagnosis, azole resistance, diabetes or immunosuppression, but also an entirely non-fungal disorder. Postmenopausal bleeding, blood-stained discharge, a non-healing lesion or architectural change requires assessment for neoplasia. In a child, discharge and irritation need a paediatric differential and safeguarding approach, not adult VVC treatment by default.
Management
For uncomplicated VVC, use one effective short-course topical azole or a suitable oral regimen in a nonpregnant patient. Explain application, likely local burning, oral adverse effects and when symptoms should improve. Complete the chosen regimen and avoid combining multiple antifungals. External comfort measures include avoiding fragranced products and friction; the vagina does not need douching. Probiotics, homeopathy and restrictive anti-Candida diets are not established replacements for antifungal therapy.
Pregnancy requires a recommended topical course, commonly seven days, rather than oral fluconazole. Confirm pregnancy possibility before an oral dose. For severe VVC, use a longer topical azole course or an appropriately spaced oral regimen only in a suitable nonpregnant patient. Recurrent C. albicans VVC requires mycological confirmation, longer induction to achieve remission and then suppressive maintenance; suppression controls symptoms but is rarely curative indefinitely. Review interactions, liver risk and adherence during prolonged oral therapy.
For non-albicans VVC, first confirm that yeast explains the symptoms. Use species information and a longer non-fluconazole azole course according to specialist or guideline advice. Intravaginal boric acid is a limited option for selected recurrence, not first-line self-care: it is toxic if swallowed, must be stored away from children and is contraindicated in pregnancy. Persistent culture-positive disease merits susceptibility testing and specialist management.
Routine treatment of an asymptomatic sex partner is not recommended. A partner with symptomatic balanitis can receive topical antifungal treatment for symptom relief. Offer STI testing based on risk rather than because candidiasis is an STI. Follow-up is not required after uncomplicated resolution. Return for persistence, recurrence within two months, three or more episodes in a year, severe symptoms, pregnancy, diabetes or immunosuppression, or any pain, fever, bleeding, ulcer or treatment reaction. At review, reconsider the diagnosis rather than simply repeating fluconazole.
Prescribing Information
WHO 2024 suggests several options for adults and adolescents with C. albicans VVC: oral fluconazole 150 to 200 mg once; clotrimazole 500 mg intravaginally once, 200 mg daily for three days, or a specified intravaginal cream regimen; miconazole 1200 mg intravaginally once or 400 mg daily for seven days; econazole 150 mg intravaginally once; or nystatin 100,000 units intravaginally twice daily for 15 days. Use a formulation actually authorised and available in India and follow its applicator or pessary instructions. Do not combine options without a clinical reason.
For pregnancy, WHO suggests clotrimazole 100 mg intravaginally daily for seven days or 1% cream daily for seven days, or nystatin 100,000 units intravaginally twice daily for 15 days. CDC likewise recommends only topical azoles for seven days in pregnancy and advises against a single oral fluconazole dose. Verify pregnancy before oral therapy. Topical azole creams and suppositories can be oil-based and may weaken latex condoms or diaphragms; use the product-specific interval.
For recurrent C. albicans VVC, CDC recommends induction with seven to fourteen days of topical treatment or fluconazole 100, 150 or 200 mg orally on days 1, 4 and 7, followed by the same oral dose weekly for six months when suitable. This is a clinician-managed programme, not a standing self-prescription. Check liver disease, pregnancy prevention, QT risk and clinically important interactions, and consider liver tests according to the patient and local protocol. Suppression is effective for control but rarely permanently curative.
For severe nonpregnant disease, CDC uses seven to fourteen days of topical azole or two 150 mg fluconazole doses 72 hours apart. For non-albicans recurrence, a specialist may consider boric acid 600 mg vaginally daily for three weeks after a longer non-fluconazole azole course; never use it orally or in pregnancy. Culture, species and susceptibility matter before repeated therapy. Oral azoles can cause nausea, abdominal pain, headache, liver enzyme abnormalities and important interactions. Persistent symptoms after correct treatment require re-examination, not indefinite azole exposure.
When to Refer
Refer urgently for pregnancy with abdominal pain, bleeding, fever or fluid leakage; severe lower abdominal pain or pelvic tenderness; sepsis; haemodynamic instability; urinary retention; rapidly spreading vulval swelling or necrosis; or a severe allergic or mucocutaneous drug reaction. These are not routine uncomplicated candidiasis. Provide acute care and evaluate ectopic pregnancy, PID, abscess, bacterial soft-tissue infection or another emergency.
Use urgent gynaecology, dermatology or cancer assessment for postmenopausal bleeding, persistent blood-stained discharge, a non-healing ulcer or fissure, vulval architectural change, pigment change, a cervical lesion, pelvic mass or unexplained systemic symptoms. A child with discharge or genital inflammation needs paediatric assessment and safeguarding; adult internal examination and empirical fluconazole are inappropriate defaults.
Refer for recurrent VVC with three or more symptomatic episodes in a year, severe disease, non-albicans species, suspected azole resistance, persistent positive culture despite maintenance, poorly controlled diabetes, HIV or other immunosuppression, pregnancy with treatment failure, or significant medicine interactions. Specialist input is appropriate before long-term suppression or boric acid. Culture and susceptibility access may require a tertiary laboratory or NACO-linked service.
Refer when symptoms persist but microscopy and culture are repeatedly negative. Dermatological disease, vulvodynia, genitourinary syndrome of menopause, desquamative inflammatory vaginitis, contact allergy or cervicitis may need different expertise. Send the episode timeline, objective findings, species, susceptibility if available, medicines and adherence. Calling every recurrence resistant thrush without evidence delays the correct diagnosis.
Red Flags
VVC should not cause high fever, severe lower abdominal pain, cervical-motion or adnexal tenderness, haemodynamic compromise or systemic toxicity. These findings suggest PID, abscess, pregnancy complication or another acute illness. Severe pain out of proportion, spreading erythema, necrosis or crepitus raises concern for bacterial soft-tissue infection, especially with diabetes or immunosuppression. Pregnancy with pain, bleeding, syncope or shoulder-tip pain requires urgent ectopic assessment.
Bleeding is not a typical candidiasis feature. Postmenopausal, postcoital or persistent intermenstrual bleeding, blood-stained watery discharge, a friable cervix, non-healing ulcer, vulval architectural loss or mass needs directed evaluation. Fissures can occur in severe VVC, but persistent or recurrent fissuring warrants herpes and dermatosis assessment. A retained foreign body can cause offensive discharge; continuous urine or faecal leakage suggests fistula.
Medicine red flags include facial or tongue swelling, breathing difficulty, widespread rash, mucosal blistering, jaundice, dark urine, severe vomiting, syncope, palpitations or suspected major interaction. Accidental oral ingestion of boric acid is a poisoning emergency. Oral fluconazole exposure in pregnancy needs clinician review, not panic or repeated dosing. Severe liver disease and complex polypharmacy require alternative selection.
Diagnostic red flags include repeated empirical antifungal use without yeast demonstration, recurrence within two months, three or more episodes yearly, culture-positive non-albicans yeast with minimal symptoms, or culture-negative symptoms that never respond. These patterns demand confirmation and a broader differential. Safeguarding concerns, assault, coercion or symptoms in a child require an appropriate confidential pathway.
Indian Clinical Context
NACO's National Technical Guidelines on STI and RTI 2024 are the India-specific programme anchor. Candida is included among common causes of vaginal discharge syndrome, and enhanced syndromic management provides immediate care where microscopy or follow-up is unavailable. The guideline also promotes etiological diagnosis where possible. Apply the full flowchart, including pregnancy, cervicitis risk, lower abdominal pain and referral, rather than dispensing an antifungal solely because discharge is white. Confirm current colour-coded kit contents and do not advertise a kit as proof of infection.
Microscopy, culture and susceptibility availability varies. At primary care, a carefully collected wet mount and vaginal pH can prevent many incorrect treatments. At district or tertiary level, recurrent, complicated or non-responsive disease deserves species identification and, when persistent culture positivity follows maintenance, susceptibility testing. Candida glabrata may be missed because it does not form typical hyphae. A laboratory report must still be interpreted with symptoms because colonisation is common.
Use generic medicines, verify CDSCO-authorised formulations and current pregnancy labelling, and account for affordability. A single oral tablet may seem convenient, but pregnancy, liver disease and interactions can make topical therapy safer. Do not promote fixed-dose vaginal combinations, probiotics, washes or restrictive diets as universally superior. Counsel in the patient's preferred language that VVC is common, not proof of poor hygiene or infidelity, and usually not sexually transmitted.
NACO Suraksha Clinics and teaching hospitals can support difficult diagnosis, STI testing and partner counselling when another infection is possible. Diabetes services are relevant when recurrent disease and hyperglycaemic symptoms coexist. Teleconsultation can review results or adherence, but severe inflammation, recurrence and uncertain diagnosis need examination and samples. Provide clear storage warnings if a specialist prescribes boric acid and ensure it is never used in pregnancy or swallowed. Quality care avoids both under-treatment and endless over-the-counter azole cycles.
NMC Competency Mapping
NMC OG22.2 explicitly includes Candida in the aetiology, characteristics, clinical diagnosis, investigations, genital hygiene, common-cause management and syndromic management of vaginal discharge. The learner should distinguish Candida colonisation from symptomatic vulvovaginitis, describe itch, soreness, external dysuria, vulval erythema, fissures and typical discharge, and know that none is individually specific. OG22.1 supplies the physiological comparison.
Diagnostic competence includes vaginal pH usually below 4.5, saline and 10% potassium-hydroxide microscopy for budding yeast, hyphae or pseudohyphae, and culture or validated molecular testing when wet mount is negative or disease complicated. Learners should know that C. glabrata may not form hyphae and that an asymptomatic positive culture is not treated. Differential diagnosis includes BV, trichomoniasis, cervicitis, PID, herpes, contact dermatitis, dermatoses and menopausal change.
DR10.10 and OG35.5 require diagnosis, examination and management of a vaginal-discharge case; GM26.26 covers candidiasis more broadly. A strong prescription answer classifies uncomplicated versus complicated disease, checks pregnancy and interactions, selects one effective topical or oral regimen, uses topical therapy in pregnancy and knows when recurrent disease requires induction plus maintenance. It does not prescribe partner treatment routinely or claim probiotics cure VVC.
For OSCE performance, obtain privacy and consent, ask about recurrence, pregnancy, antibiotics, diabetes, immunosuppression and self-treatment, inspect the vulva, collect vaginal material correctly and interpret pH and microscopy. Explain the diagnosis without stigma, give application or dosing instructions, discuss barrier-product effects and arrange review for persistence, recurrence, severe disease or red flags.
Key Exam Pearls for NEET PG
VVC is usually caused by C. albicans and produces pruritus, soreness, vulval erythema, oedema, fissures, external dysuria and sometimes curdy discharge. Vaginal pH is usually below 4.5. Demonstrate budding yeast, hyphae or pseudohyphae using saline or 10% KOH; culture is the reference standard when microscopy is negative or disease is complicated. Do not treat asymptomatic Candida colonisation.
Uncomplicated means sporadic or infrequent, mild to moderate, likely C. albicans and non-immunocompromised. Complicated includes recurrent, severe, non-albicans or an abnormal host such as poorly controlled diabetes or immunosuppression. CDC defines recurrent VVC as three or more symptomatic episodes in under one year. C. glabrata does not readily form hyphae and can be missed on microscopy.
Use a short-course topical azole or single oral fluconazole for suitable nonpregnant uncomplicated disease. In pregnancy use a recommended topical azole for seven days; avoid oral fluconazole. Severe disease needs seven to fourteen days topical therapy or, if nonpregnant and suitable, two fluconazole doses 72 hours apart. Recurrent C. albicans disease uses longer induction then weekly suppression for six months. Maintenance controls but rarely cures permanently.
Routine partner treatment is not recommended; treat symptomatic balanitis. Probiotics and homeopathy are not established treatment. Boric acid is a specialist option for selected recurrent non-albicans disease, toxic if swallowed and contraindicated in pregnancy. Pain, fever, pelvic tenderness, bleeding, ulcers or systemic toxicity are not routine VVC and require a broader diagnosis.
Frequently Asked Questions
Can a positive Candida culture occur without a yeast infection?
Yes. Candida can colonise the vagina without causing symptoms, and a positive culture alone is not an indication for treatment. VVC requires compatible itch, soreness, inflammation, external dysuria or discharge plus microscopy, culture or a validated test interpreted in context. This is especially important for non-albicans Candida, which may be found in minimally symptomatic people. Treating colonisation exposes patients to adverse effects and can delay diagnosis of BV, trichomoniasis, dermatitis or another cause.
Why is oral fluconazole avoided for candidiasis during pregnancy?
Pregnancy changes the recommended risk-benefit choice. WHO 2024 suggests topical clotrimazole for seven days or intravaginal nystatin options, and CDC recommends topical azoles for seven days rather than oral fluconazole. A clinician should confirm pregnancy possibility before an oral dose. Accidental exposure needs individual review, but the routine response is not to repeat it or self-medicate. Pain, bleeding, fever or fluid leakage in pregnancy requires obstetric assessment beyond candidiasis treatment.
When is vulvovaginal candidiasis classified as recurrent disease?
CDC defines recurrent VVC as three or more symptomatic episodes in less than one year. The diagnosis should be confirmed with culture or a validated test because repeated itch is not always yeast. Clinicians assess species, recent antibiotics, diabetes, immunosuppression, adherence and alternative vulval disease. Confirmed recurrent C. albicans VVC often needs a longer induction phase followed by weekly suppressive fluconazole for six months when safe, with pregnancy, liver and interaction review.
Should sexual partners receive treatment for vulvovaginal candidiasis?
Routine treatment of an asymptomatic partner is not recommended because uncomplicated VVC is not usually acquired through sexual intercourse. A partner with symptomatic balanitis, such as glans redness and itch, may benefit from a topical antifungal for symptom relief. Persistent symptoms after sex still need diagnostic review because friction, condoms, lubricants, BV, trichomoniasis, cervicitis or contact allergy may be responsible. Partner STI testing is offered according to exposure, not simply because Candida was detected.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic